A study carried out at Victoria, and recently published online in the international scientific journal PLOS ONE, holds promise for patients suffering from secondary progressive MS, an advanced form of the disease, which causes nerve degeneration leading to impaired vision and coordination, and eventually, paralysis.
The study focused on understanding how a new MS drug, MIS416, developed by the
The team of scientists includes Dr
"We know this drug works, but we are not sure why. This study has helped us understand the pathways that are driving the disease and how the medication alters the immune system, giving us a better idea of why MIS416 works as well as insight into how to treat patients and predict who will do better on this sort of medication," says Dr La Flamme.
Most people believe MS revolves around T cells, says Dr La Flamme, but the Victoria study reveals that targeting other cells in the central nervous system can significantly reduce advanced forms of MS.
You can read the full article here: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0087712
TNS 24KuanRap-140204 30FurigayJof-4625393 30FurigayJof
Most Popular Stories
- Koch Brothers Step up Anti-Obamacare Campaign
- FDIC Sues Big Banks Over Rate Manipulation
- Vybz Kartel Convicted of Murder
- Stocks Close Lower Ahead of Crimea Vote
- Is Malaysian Airlines Flight 370 in Andaman Sea?
- SoCalGas Reaches Record Spend on Diversity Suppliers
- Ulta Shares Look Good on Strong Q4
- Jittery Investors Dumping Russian Stocks
- FDIC Accuses Big Banks of Fraud, Conspiracy
- U.S. Consumer Sentiment Falls in Early March